Skip to main content

Table 1 Clinical characteristics for PCI and medical group in very elderly female ACS patients

From: Improvement of long-term clinical outcomes by successful PCI in the very elderly women with ACS

Variables Before PS match P value After PS match P value
PCI group (n = 232) Medical group (n = 497) PCI group (n = 129) Medical group (n = 129)
Demographic
 Age (years) 82 (81, 84) 82 (81, 85) 0.082 82 (81, 84) 82 (81, 85) 0.273
 BMI (kg/m2) 24.4 (22.3, 27.0) 24.4 (22.0, 26.9 0.6 24.4 (22.6, 27.3) 24.0 (21.9, 27.3) 0.327
Initial presentation
 Heart rate (beats/min) 70 (65, 79) 70 (63, 81) 0.961 70 (64, 76) 72 (65, 84) 0.057
 Systolic BP (mmHg) 134 (120, 149) 133 (122, 147) 0.782 135 (124, 149) 130 (120, 148) 0.168
 Diastolic BP (mmHg) 70 (62, 79) 70 (64, 80) 0.371 70 (63, 77) 70 (64, 80) 0.733
Past medical history
 Hypertension, n (%) 185 (79.9) 422 (84.9) 0.082 102 (79.1) 108 (83.7) 0.337
 Diabetes mellitus, n (%) 92 (39.7) 175 (35.2) 0.246 48 (37.2) 49 (38.0) 0.898
 Dyslipidemia, n (%) 96 (41.4) 216 (43.5) 0.597 54 (41.9) 44 (34.1) 0.20
 Prior MI, n (%) 17 (7.3) 51 (10.3) 0.202 9 (7.0) 9 (7.0) 0.986
 Prior stroke, n (%) 56 (24.1) 137 (27.6) 0.329 30 (23.3) 31 (24.0) 0.884
 Smoking, n (%) 23 (9.9) 29 (5.8) 0.046 8 (6.2) 10 (7.8) 0.625
 Prior PAD, n (%) 2 (1.0) 3 (0.7) 0.688 0 (0) 3 (2.4) 0.247
Clinical diagnosis
 UAP, n (%) 111 (47.8) 343 (69.0) < 0.001 66 (51.2) 58 (45.0) 0.319
 NSTEMI, n (%) 55 (23.7) 104 (20.9) 0.397 41 (31.8) 42 (32.6) 0.894
 STEMI, n (%) 66 (28.4) 50 (10.1) < 0.001 22 (17.1) 29 (22.5) 0.274
 Length of stay (days) 7 (6, 10) 7 (6, 10) 0.461 7 (6, 10) 8 (6, 11) 0.173
Laboratory finding
 HbA1c (%) 6.2 (5.7, 7.2) 6.1 (5.7, 6.9) 0.30 6.3 (5.7, 7.2) 6.2 (5.7, 7.0) 0.753
 TC (mmol/L) 4.41 (3.69, 5.26) 4.26 (3.60, 5.02) 0.087 4.4 (3.70, 5.1) 4.3 (3.6, 5.2) 0.683
 LDL-C (mmol/L) 2.46 (1.99, 3.03) 2.34 (1.81, 2.89) 0.012 2.49 (1.96, 2.99) 2.43 (1.91, 2.97) 0.510
 TG (mmol/L) 1.32 (0.96, 1.85) 1.24 (0.90, 1.67) 0.052 1.32 (0.98, 1.84) 1.22 (0.89, 1.67) 0.183
 Creatinine (umol/L) 76.3 (65.9, 91.7) 79.5 (67.9, 100.2) 0.016 79 (66.6, 95.7) 81.6 (68.4, 99.1) 0.299
 ALT (U/L) 15 (10, 21.8) 13 (10, 20) 0.024 15 (11, 21) 14 (10, 22) 0.586
 CK-MB (ng/ml) 1.7 (1.1, 4.05) 1.4 (0.9, 2.53) 0.002 1.7 (1.1, 4.5) 1.8 (1.08, 5.95) 0.553
 log NT-proBNP 2.93 (2.56, 3.42) 3.05 (2.49, 3.58) 0.231 2.92 (2.56, 3.45) 3.34 (2.86, 3.82) < 0.001
 LVEF ≥ 50%, n (%) 197 (87.2) 414 (87.3) 0.949 111 (86.7) 102 (82.3) 0.328
  1. *P2Y12 receptor antagonist within 12 months after PCI. P, level of statistical significance
  2. BMI body mass index, BP blood pressure, MI myocardial infarction, PAD peripheral artery disease, UAP unstable angina pectoris, NSTEMI non-ST-segment elevation myocardial infarction, STEMI ST-elevation myocardial infarction, HbA1c Hemoglobin A1c, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, TG triglyceride, ALT alanine aminotransferase, CK-MB creatine kinase-MB, NT-proBNP N-Terminal pro-brain natriuretic peptide, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers